• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nimbus raises $24 million to launch new biotech model

Nimbus raises $24 million to launch new biotech model

June 28, 2011
CenterWatch Staff

A Cambridge, Mass.-based biotech startup with big plans for computational drug discovery work has lined up a $24 million financing round with the help of some high-profile investors, including Microsoft's billionaire chairman Bill Gates, according to FierceBiotech.

Nimbus Discovery said it raised $24 million from Gates, SR One (the corporate venture arm of GlaxoSmithKline) and Lilly Ventures, which all joined with the founding investors at Atlas Venture.

Nimbus is building its pipeline on the premise that it has access to the kind of discovery technology can lead to new drugs to hit some of the hardest targets in biotech. Its first targets are IRAK4 and ACC for inflammation, cancer and metabolic disease. Nimbus said it has already done significant pre-clinical work on IRAK4, which has implications for non-Hodgkin's lymphoma and inflammation. And there are plans to add to the list of targets.

What makes Nimbus unique is its plan for a series of new drug programs, creating individual subsidiaries that can be sold off to pharma companies at an early point in development. An ultra-virtual company that's now two people—CSO Rosanna Kapeller and CBO Jonathan Montagu—Nimbus is using Schrodinger, a company co-founded by Columbia University's Richard Friesner, to provide the platform while Nimbus focuses on product development.

An early deal would both “help prove that this is an exciting new model for biotech," said Montagu, and start delivering relatively quick returns for the company's investors, as opposed to the standard model of delivering a single big exit with a buyout or IPO.

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing